학술논문
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
Document Type
Article
Author
Source
In: Cancer Immunology, Immunotherapy . (Cancer Immunology, Immunotherapy, June 2021, 70(6):1583-1592)
Subject
Language
English
ISSN
14320851
03407004
03407004